A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC

Journal of Leukocyte Biology

Volumn 87, Issue 3, 2010, Pages 509-521

  Lori Blanchfield, J ^a   Mannie, Mark D ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Cytokines; DC; Rodent; T cells; Tolerogenic vaccine

Indexed keywords

COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 NEUROANTIGEN PROTEIN; ENCEPHALITOGENIC PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR NEUROANTIGEN PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYBRID PROTEIN; INTERLEUKIN 2 NEUROANTIGEN; INTERLEUKIN 4 NEUROANTIGEN; MYELIN BASIC PROTEIN; UNCLASSIFIED DRUG; ANTIGEN; ORGANIC COMPOUND; TOLEROGEN;

ALLERGIC ENCEPHALOMYELITIS; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CELL SUBPOPULATION; CONTROLLED STUDY; COVALENT BOND; DENDRITIC CELL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; DRUG UPTAKE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; T LYMPHOCYTE; TREATMENT OUTCOME; ANIMAL; ANTIBODY SPECIFICITY; CELL DIFFERENTIATION; CHEMISTRY; CYTOLOGY; DISEASE COURSE; GUINEA PIG; IMMUNOLOGY; MOUSE; PROTEIN TERTIARY STRUCTURE;

RODENTIA;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS; CELL DIFFERENTIATION; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GUINEA PIGS; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MYELIN BASIC PROTEINS; ORGAN SPECIFICITY; ORGANIC CHEMICALS; PROTEIN STRUCTURE, TERTIARY; RATS; RECOMBINANT FUSION PROTEINS;

EID: 77950346727     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0709520     Document Type: Article

References (80)

1. Goodin, D. S., Cohen, B. A., O'Connor, P., Kappos, L., Stevens, J. C. (2008) Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 71, 766-773.
2. Kleinschnitz, C., Meuth, S. G., Wiendl, P. H. (2008) The trials and errors in MS therapy. Int. MS J. 15, 79-90.
3. Linker, R. A., Kieseier, B. C., Gold, R. (2008) Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol. Sci. 29, 558-565.
4. Lutterotti, A., Sospedra, M., Martin, R. (2008) Antigen-specific therapies in MS - current concepts and novel approaches. J. Neurol. Sci. 274, 18-22.
5. Miller, S. D., Turley, D. M., Podojil, J. R. (2007) Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat. Rev. Immunol. 7, 665-677.
6. Steinman, L. (2007) Antigen-specific therapy of multiple sclerosis: the long-sought magic bullet. Neurotherapeutics 4, 661-665.
7. Miyamoto, K., Kingsley, C. I., Zhang, X., Jabs, C., Izikson, L., Sobel, R. A., Weiner, H. L., Kuchroo, V. K., Sharpe, A. H. (2005) The ICOS molecule plays a crucial role in the development of mucosal tolerance. J. Immunol. 175, 7341-7347. (Pubitemid 41713430)
8. Song, F., Guan, Z., Gienapp, I. E., Shawler, T., Benson, J., Whitacre, C. C. (2006) The thymus plays a role in oral tolerance in experimental autoimmune encephalomyelitis. J. Immunol. 177, 1500-1509. (Pubitemid 44092483)
9. Weishaupt, A., Jander, S., Bruck, W., Kuhlmann, T., Stienekemeier, M., Hartung, T., Toyka, K. V., Stoll, G., Gold, R. (2000) Molecular mechanisms of high-dose antigen therapy in experimental autoimmune encephalomyelitis: rapid induction of Th1-type cytokines and inducible nitric oxide synthase. J. Immunol. 165, 7157-7163. (Pubitemid 32001192)
10. Minguela, A., Pastor, S., Mi, W., Richardson, J. A., Ward, E. S. (2007) Feedback regulation of murine autoimmunity via dominant anti-inflammatory effects of interferon γ. J. Immunol. 178, 134-144. (Pubitemid 46033594)
11. Chan, J., Ban, E. J., Chun, K. H., Wang, S., Backstrom, B. T., Bernard, C. C., Toh, B. H., Alderuccio, F. (2008) Transplantation of bone marrow transduced to express self-antigen establishes deletional tolerance and permanently remits autoimmune disease. J. Immunol. 181, 7571-7580.
12. Sewell, D., Qing, Z., Reinke, E., Elliot, D., Weinstock, J., Sandor, M., Fabry, Z. (2003) Immunomodulation of experimental autoimmune encephalomyelitis by helminth ova immunization. Int. Immunol. 15, 59-69.
13. Chen, Y., Hancock, W. W., Marks, R., Gonnella, P., Weiner, H. L. (1998) Mechanisms of recovery from experimental autoimmune encephalomyelitis: T cell deletion and immune deviation in myelin basic protein T cell receptor transgenic mice. J. Neuroimmunol. 82, 149-159. (Pubitemid 28179917)
14. Nicholson, L. B., Greer, J. M., Sobel, R. A., Lees, M. B., Kuchroo, V. K. (1995) An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3, 397-405.
15. Young, D. A., Lowe, L. D., Booth, S. S., Whitters, M. J., Nicholson, L., Kuchroo, V. K., Collins, M. (2000) IL-4, IL-10, IL-13, and TGF-β from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J. Immunol. 164, 3563-3572. (Pubitemid 30169808)
16. Saoudi, A., Simmonds, S., Huitinga, I., Mason, D. (1995) Prevention of experimental allergic encephalomyelitis in rats by targeting autoantigen to B cells: evidence that the protective mechanism depends on changes in the cytokine response and migratory properties of the autoantigenspecific T cells. J. Exp. Med. 182, 335-344.
17. Yu, P., Gregg, R. K., Bell, J. J., Ellis, J. S., Divekar, R., Lee, H. H., Jain, R., Waldner, H., Hardaway, J. C., Collins, M., Kuchroo, V. K., Zaghouani, H. (2005) Specific T regulatory cells display broad suppressive functions against experimental allergic encephalomyelitis upon activation with cognate antigen. J. Immunol. 174, 6772-6780. (Pubitemid 40705640)
18. Zhong, M. C., Kerlero de Rosbo, N., Ben-Nun, A. (2002) Multiantigen/ multiepitope-directed immune-specific suppression of "complex autoimmune encephalomyelitis" by a novel protein product of a synthetic gene. J. Clin. Invest. 110, 81-90.
19. Elliott, E. A., Cofiell, R., Wilkins, J. A., Raine, C. S., Matis, L. A., Mueller, J. P. (1997) Immune tolerance mediated by recombinant proteolipid protein prevents experimental autoimmune encephalomyelitis. J. Neuroimmunol. 79, 1-11. (Pubitemid 27454677)
20. Ho, P. P., Fontoura, P., Platten, M., Sobel, R. A., DeVoss, J. J., Lee, L. Y., Kidd, B. A., Tomooka, B. H., Capers, J., Agrawal, A., Gupta, R., Zernik, J., Yee, M. K., Lee, B. J., Garren, H., Robinson, W. H., Steinman, L. (2005) A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/ IL-4-tolerizing DNA vaccination and treats autoimmune disease. J. Immunol. 175, 6226-6234. (Pubitemid 41508112)
21. Garren, H., Ruiz, P. J., Watkins, T. A., Fontoura, P., Nguyen, L. T., Estline, E. R., Hirschberg, D. L., Steinman, L. (2001) Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 15, 15-22. (Pubitemid 32728316)
22. Margot, C. D., Ford, M. L., Evavold, B. D. (2005) Amelioration of established experimental autoimmune encephalomyelitis by an MHC anchorsubstituted variant of proteolipid protein 139-151. J. Immunol. 174, 3352-3358.
23. Turley, D. M., Miller, S. D. (2007) Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis. J. Immunol. 178, 2212-2220.
24. McDevitt, H. (2004) Specific antigen vaccination to treat autoimmune disease. Proc. Natl. Acad. Sci. USA 101 (Suppl. 2), 14627-14630.
25. Pedotti, R., Mitchell, D., Wedemeyer, J., Karpuj, M., Chabas, D., Hattab, E. M., Tsai, M., Galli, S. J., Steinman, L. (2001) An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat. Immunol. 2, 216-222.
26. Mannie, M. D., Abbott, D. J., Blanchfield, J. L. (2009) Experimental autoimmune encephalomyelitis in Lewis rats: IFN-β acts as a tolerogenic adjuvant for induction of neuroantigen-dependent tolerance. J. Immunol. 182, 5331-5341.
27. Mannie, M. D., Abbott, D. J. (2007) A fusion protein consisting of IL-16 and the encephalitogenic peptide of myelin basic protein constitutes an antigen-specific tolerogenic vaccine that inhibits experimental autoimmune encephalomyelitis. J. Immunol. 179, 1458-1465.
28. Mannie, M. D., Clayson, B. A., Buskirk, E. J., DeVine, J. L., Hernandez, J. J., Abbott, D. J. (2007) IL-2/neuroantigen fusion proteins as antigenspecific tolerogens in experimental autoimmune encephalomyelitis (EAE): correlation of T cell-mediated antigen presentation and tolerance induction. J. Immunol. 178, 2835-2843.
29. Mannie, M. D., Devine, J. L., Clayson, B. A., Lewis, L. T., Abbott, D. J. (2007) Cytokine-neuroantigen fusion proteins: new tools for modulation of myelin basic protein (MBP)-specific T cell responses in experimental autoimmune encephalomyelitis. J. Immunol. Methods 319, 118-132.
30. Belkaid, Y., Oldenhove, G. (2008) Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity 29, 362-371.
31. Goubier, A., Dubois, B., Gheit, H., Joubert, G., Villard-Truc, F., Asselin-Paturel, C., Trinchieri, G., Kaiserlian, D. (2008) Plasmacytoid dendritic cells mediate oral tolerance. Immunity 29, 464-475.
32. Guan, Y., Yu, S., Zhao, Z., Ciric, B., Zhang, G. X., Rostami, A. (2007) Antigen presenting cells treated in vitro by macrophage colony-stimulating factor and autoantigen protect mice from autoimmunity. J. Neuroimmunol. 192, 68-78. (Pubitemid 350213118)
33. Huang, Y. M., Yang, J. S., Xu, L. Y., Link, H., Xiao, B. G. (2000) Autoantigen-pulsed dendritic cells induce tolerance to experimental allergic encephalomyelitis (EAE) in Lewis rats. Clin. Exp. Immunol. 122, 437-444.
34. Khoury, S. J., Gallon, L., Chen, W., Betres, K., Russell, M. E., Hancock, W. W., Carpenter, C. B., Sayegh, M. H., Weiner, H. L. (1995) Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J. Exp. Med. 182, 357-366.
35. Li, H., Zhang, G. X., Chen, Y., Xu, H., Fitzgerald, D. C., Zhao, Z., Rostami, A. (2008) CD11c+CD11b+ dendritic cells play an important role in intravenous tolerance and the suppression of experimental autoimmune encephalomyelitis. J. Immunol. 181, 2483-2493.
36. Miyake, Y., Asano, K., Kaise, H., Uemura, M., Nakayama, M., Tanaka, M. (2007) Critical role of macrophages in the marginal zone in the suppression of immune responses to apoptotic cell-associated antigens. J. Clin. Invest. 117, 2268-2278.
37. Cools, N., Ponsaerts, P., Van Tendeloo, V. F., Berneman, Z. N. (2007) Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J. Leukoc. Biol. 82, 1365-1374.
38. Yamazaki, S., Dudziak, D., Heidkamp, G. F., Fiorese, C., Bonito, A. J., Inaba, K., Nussenzweig, M. C., Steinman, R. M. (2008) CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J. Immunol. 181, 6923-6933.
39. Yamazaki, S., Steinman, R. M. (2009) Dendritic cells as controllers of antigen- specific Foxp3+ regulatory T cells. J. Dermatol. Sci. 54, 69-75.
40. Hamilton, J. A. (2008) Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8, 533-544.
41. Conti, L., Gessani, S. (2008) GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances. Immunobiology 213, 859-870.
42. Blank, K., Lindner, P., Diefenbach, B., Pluckthun, A. (2002) Self-immobilizing recombinant antibody fragments for immunoaffinity chromatography: generic, parallel, and scalable protein purification. Protein Expr. Purif. 24, 313-322.
43. Mannie, M. D., Norris, M. S. (2001) MHC class-II-restricted antigen presentation by myelin basic protein-specific CD4+ T cells causes prolonged desensitization and outgrowth of CD4- responders. Cell. Immunol. 212, 51-62.
44. Patel, D. M., Arnold, P. Y., White, G. A., Nardella, J. P., Mannie, M. D. (1999) Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition. J. Immunol. 163, 5201-5210.
45. Mannie, M. D., Fraser, D. J., McConnell, T. J. (2003) IL-4 responsive CD4+ T cells specific for myelin basic protein: IL-2 confers a prolonged postactivation refractory phase. Immunol. Cell Biol. 81, 8-19.
46. Woollett, G. R., Barclay, A. N., Puklavec, M., Williams, A. F. (1985) Molecular and antigenic heterogeneity of the rat leukocyte-common antigen from thymocytes and T and B lymphocytes. Eur. J. Immunol. 15, 168-173.
47. Patel, D. M., Dudek, R. W., Mannie, M. D. (2001) Intercellular exchange of class II MHC complexes: ultrastructural localization and functional presentation of adsorbed I-A/peptide complexes. Cell. Immunol. 214, 21-34.
48. Chen, T. T., Tao, M. H., Levy, R. (1994) Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocytemacrophage colony-stimulating factor. J. Immunol. 153, 4775-4787.
49. Tao, M. H., Levy, R. (1993) Idiotype/granulocyte-macrophage colonystimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362, 755-758.
50. Schwegler, C., Dorn-Beineke, A., Nittka, S., Stocking, C., Neumaier, M. (2005) Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice. Cancer Res. 65, 1925-1933. (Pubitemid 40478622)
51. Wortham, C., Grinberg, L., Kaslow, D. C., Briles, D. E., McDaniel, L. S., Lees, A., Flora, M., Snapper, C. M., Mond, J. J. (1998) Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2. Infect. Immun. 66, 1513-1520.
52. Tso, C. L., Zisman, A., Pantuck, A., Calilliw, R., Hernandez, J. M., Paik, S., Nguyen, D., Gitlitz, B., Shintaku, P. I., de Kernion, J., Figlin, R., Belldegrun, A. (2001) Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res. 61, 7925-7933. (Pubitemid 33049383)
53. Rodriguez, D., Rodriguez, J. R., Llorente, M., Vazquez, I., Lucas, P., Esteban, M., Martinez, A. C., del Real, G. (1999) A human immunodefi- ciency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine. J. Gen. Virol. 80, 217-223.
54. Picca, C. C., Larkin III, J., Boesteanu, A., Lerman, M. A., Rankin, A. L., Caton, A. J. (2006) Role of TCR specificity in CD4+ CD25+ regulatory T-cell selection. Immunol. Rev. 212, 74-85.
55. Larkin III, J., Rankin, A. L., Picca, C. C., Riley, M. P., Jenks, S. A., Sant, A. J., Caton, A. J. (2008) CD4+CD25+ regulatory T cell repertoire formation shaped by differential presentation of peptides from a self-antigen. J. Immunol. 180, 2149-2157.
56. Cunningham, M. W. (2003) Autoimmunity and molecular mimicry in the pathogenesis of post-streptococcal heart disease. Front. Biosci. 8, s533-s543.
57. Guilherme, L., Ramasawmy, R., Kalil, J. (2007) Rheumatic fever and rheumatic heart disease: genetics and pathogenesis. Scand. J. Immunol. 66, 199-207.
58. Ioachimescu, O. C., Kavuru, M. S. (2006) Pulmonary alveolar proteinosis. Chron. Respir. Dis. 3, 149-159.
59. Pette, M., Fujita, K., Kitze, B., Whitaker, J. N., Albert, E., Kappos, L., Wekerle, H. (1990) Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 40, 1770-1776.
60. McQualter, J. L., Darwiche, R., Ewing, C., Onuki, M., Kay, T. W., Hamilton, J. A., Reid, H. H., Bernard, C. C. (2001) Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J. Exp. Med. 194, 873-882.
61. Ponomarev, E. D., Shriver, L. P., Maresz, K., Pedras-Vasconcelos, J., Verthelyi, D., Dittel, B. N. (2007) GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J. Immunol. 178, 39-48. (Pubitemid 46039660)
62. Aloisi, F., De Simone, R., Columba-Cabezas, S., Penna, G., Adorini, L. (2000) Functional maturation of adult mouse resting microglia into an APC is promoted by granulocyte-macrophage colony-stimulating factor and interaction with Th1 cells. J. Immunol. 164, 1705-1712. (Pubitemid 30108719)
63. King, I. L., Dickendesher, T. L., Segal, B. M. (2009) Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 113, 3190-3197.
64. Marusic, S., Miyashiro, J. S., Douhan III, J., Konz, R. F., Xuan, D., Pelker, J. W., Ling, V., Leonard, J. P., Jacobs, K. A. (2002) Local delivery of granulocyte macrophage colony-stimulating factor by retrovirally transduced antigen-specific T cells leads to severe, chronic experimental autoimmune encephalomyelitis in mice. Neurosci. Lett. 332, 185-189.
65. Kroenke, M. A., Carlson, T. J., Andjelkovic, A. V., Segal, B. M. (2008) IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205, 1535-1541.
66. Ganesh, B. B., Cheatem, D. M., Sheng, J. R., Vasu, C., Prabhakar, B. S. (2009) GM-CSF-induced CD11c+CD8a-dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis. Int. Immunol. 21, 269-282.
67. Gaudreau, S., Guindi, C., Menard, M., Besin, G., Dupuis, G., Amrani, A. (2007) Granulocyte-macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells. J. Immunol. 179, 3638-3647.
68. Sheng, J. R., Li, L., Ganesh, B. B., Vasu, C., Prabhakar, B. S., Meriggioli, M. N. (2006) Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of FoxP3+ regulatory T cells. J. Immunol. 177, 5296-5306. (Pubitemid 44527602)
69. Sheng, J. R., Li, L. C., Ganesh, B. B., Prabhakar, B. S., Meriggioli, M. N. (2008) Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin. Immunol. 128, 172-180.
70. Kared, H., Leforban, B., Montandon, R., Renand, A., Layseca Espinosa, E., Chatenoud, L., Rosenstein, Y., Schneider, E., Dy, M., Zavala, F. (2008) Role of GM-CSF in tolerance induction by mobilized hematopoietic progenitors. Blood 112, 2575-2578.
71. Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., Rivoltini, L. (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25, 2546-2553.
72. Serafini, P., Carbley, R., Noonan, K. A., Tan, G., Bronte, V., Borrello, I. (2004) High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64, 6337-6343. (Pubitemid 39129439)
73. Sotomayor, E. M., Fu, Y. X., Lopez-Cepero, M., Herbert, L., Jimenez, J. J., Albarracin, C., Lopez, D. M. (1991) Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. J. Immunol. 147, 2816-2823.
74. Tang, H., Guo, Z., Zhang, M., Wang, J., Chen, G., Cao, X. (2006) Endothelial stroma programs hematopoietic stem cells to differentiate into regulatory dendritic cells through IL-10. Blood 108, 1189-1197. (Pubitemid 44232014)
75. Zhang, M., Tang, H., Guo, Z., An, H., Zhu, X., Song, W., Guo, J., Huang, X., Chen, T., Wang, J., Cao, X. (2004) Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat. Immunol. 5, 1124-1133.
76. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J. V., Steinman, R. M., Nussenzweig, M. C. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779.
77. Witmer-Pack, M. D., Swiggard, W. J., Mirza, A., Inaba, K., Steinman, R. M. (1995) Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. II. Expression in situ in lymphoid and nonlymphoid tissues. Cell. Immunol. 163, 157-162.
78. Bonifaz, L., Bonnyay, D., Mahnke, K., Rivera, M., Nussenzweig, M. C., Steinman, R. M. (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196, 1627-1638.
79. Trumpfheller, C., Finke, J. S., Lopez, C. B., Moran, T. M., Moltedo, B., Soares, H., Huang, Y., Schlesinger, S. J., Park, C. G., Nussenzweig, M. C., Granelli-Piperno, A., Steinman, R. M. (2006) Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J. Exp. Med. 203, 607-617.
80. Hawiger, D., Masilamani, R. F., Bettelli, E., Kuchroo, V. K., Nussenzweig, M. C. (2004) Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 20, 695-705. (Pubitemid 38757440)